Journal: NPJ Vaccines

Article Title: Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice

doi: 10.1038/s41541-021-00345-0

Figure Lengend Snippet: PfCSP mRNA (TriLink) was encapsulated in three different LNP formulations. BALB/c were injected with 10 µg and 30 µg dose of PfCSP mRNA-LNPs in a 3 week interval prime:boost regimen ( N = 5 per group). Serum and splenocytes were collected two weeks following the boost injection. a PfCSP antibody responses were determined by r-PfCSP titration ELISA and reported as the geometric mean (GM) with 95% confidence intervals (CI). b Avidity indices were calculated using a chaotrope-based avidity r-PfCSP titration ELISA and reported as the GM with 95% CI. c Functional activity of the antibodies was quantified by ILSDA using pooled mouse serum of each group. Inhibition was reported as the mean of assay replicates and calculated relative to the mean of sporozoite invasion in the absence of mouse serum. For d IFN-γ, e TNF-α, f IL-2, and g IL-12p70, splenocytes were incubated in the presence of a PfCSP overlapping 15-mer peptide pool. Cell culture supernatants were harvested after 48 h and cytokine concentrations quantified by MSD. Data are reported as the mean and standard error of the mean (SEM). All statistical analyses were performed using a Mann Whitney test (* p < 0.05; ** p < 0.01).

Article Snippet: To explore a single-dose regimen and an extended interval between doses for PfCSP mRNA (TriLink), mice were immunized either once with a 30 µg dose PfCSP mRNA-LNP1 (0–30 µg) or twice with 10 µg doses in a 3 week interval (0,3 - 10 µg) or 4 week interval (0,4 - 10 µg).

Techniques: Injection, Titration, Enzyme-linked Immunosorbent Assay, Functional Assay, Activity Assay, Inhibition, Incubation, Cell Culture, MANN-WHITNEY

Journal: NPJ Vaccines

Article Title: Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice

doi: 10.1038/s41541-021-00345-0

Figure Lengend Snippet: A 10 µg and 30 µg dose PfCSP mRNA-LNP1 (TriLink) prime:boost regimen at a 3-week interval was tested in a Pb(ANKA)-PfCSP (NF54/3D7) transgenic challenge experiment ( N = 10 per group) with 1000 sporozoites injected intravenously. a Kaplan–Meier survival curves report the percent survival of infected mice. Efficacy was calculated against the negative controls (LNP1 alone and naïve controls). Survival was defined as mice without detectable parasitemia by thin blood smear by day 14. b Fine specificity ELISAs were performed to quantify IgG responses to the r-PfCSP protein, the (NANP) 6 repeat region, and the α-TSR domain peptides. Data are reported as the GM with 95% CI. c To capture the IgG subclasses elicited by PfCSP mRNA-LNP1, r-PfCSP ELISAs were performed and IgG1, IgG2a, and IgG2b OD 1.0 titers reported. Data in the bar graph are reported as the GM with 95% CI. Pie charts are representative of the relative response of each subclass. To assess the influence of an additional booster dose in a 3-week immunization regimen, mice were immunized in a prime:boost (2x) ( N = 15 per group) and prime:boost:boost (3x) regimen ( N = 10 per group). IgG was quantified for d r-PfCSP, α-TSR domain, (NANP) 6 repeat peptide and e IgG subclass. All statistical analyses were performed using a Mann Whitney test (* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001).

Article Snippet: To explore a single-dose regimen and an extended interval between doses for PfCSP mRNA (TriLink), mice were immunized either once with a 30 µg dose PfCSP mRNA-LNP1 (0–30 µg) or twice with 10 µg doses in a 3 week interval (0,3 - 10 µg) or 4 week interval (0,4 - 10 µg).

Techniques: Transgenic Assay, Injection, Infection, MANN-WHITNEY

Journal: NPJ Vaccines

Article Title: Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice

doi: 10.1038/s41541-021-00345-0

Figure Lengend Snippet: A 10 μg dose of PfCSP mRNA, TriLink and UPenn, prime:boost (2x) or prime:boost:boost (3x) regimen at a 3 week or 6 week interval was tested in a Pb(ANKA)-PfCSP (NF54/3D7) transgenic challenge model ( N = 10 for all groups except LNP1 Alone, N = 5) with 1000 sporozoites injected intravenously, two weeks post final immunization. a – b Kaplan–Meier curves depict the percent survival of challenged mice with a 3 week and b 6 week immunization schedules and are extrapolated from the negative controls’ (LNP1 Alone and Naïve) survival percentage. Survival was defined as mice without detectable parasitemia by thin blood smear. PfCSP antibody responses were determined by c r-PfCSP ELISA, d fine specificity ELISA against the (NANP)6 repeat peptide, e the ratio of the (NANP)6 titer to the α-TSR titer, f the ratio of r-PfCSP IgG subclass titers for IgG2a and IgG1, and g r-PfCSP avidity ELISA ( N = 15 UPenn 3x, TriLink 3x, TriLink 2x) ( N = 8 LNP1 Alone). Uninfected, infected, and unchallenged mice are represented by black, red, and gray symbols, respectively. Data in the bar graphs are reported as the GM with 95% CI. All statistical analyses were performed using one-way ANOVA on ranks, Kruskal-Wallis post hoc Dunn’s multiple comparison test (** = p < 0.01; *** = p < 0.001).

Article Snippet: To explore a single-dose regimen and an extended interval between doses for PfCSP mRNA (TriLink), mice were immunized either once with a 30 µg dose PfCSP mRNA-LNP1 (0–30 µg) or twice with 10 µg doses in a 3 week interval (0,3 - 10 µg) or 4 week interval (0,4 - 10 µg).

Techniques: Transgenic Assay, Injection, Enzyme-linked Immunosorbent Assay, Infection

Journal: NPJ Vaccines

Article Title: Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice

doi: 10.1038/s41541-021-00345-0

Figure Lengend Snippet: A 10 μg dose of PfCSP mRNA-LNP1, TriLink, and UPenn, prime:boost (2x) or prime:boost:boost (3x) regimen on a 3-week interval was tested against Pb(ANKA)-PfCSP (Wellcome) transgenic parasites ( N = 15 per group for TriLink 3x and naïve controls) ( N = 10, UPenn 3x) ( N = 5 per group for TriLink 2x and LNP1 alone) with 1000 sporozoites injected intravenously, 2 weeks post final immunization. a Kaplan–Meier curves report the percent survival of challenged mice. Efficacy was calculated against the negative controls (LNP1 alone and naïve controls). Survival was defined as mice without detectable parasitemia by thin blood smear by day 14. b Functional activity of the antibodies was quantified by the ILSDA using pooled mouse serum of each group. Inhibition was calculated relative to the mean of sporozoite invasion in the absence of mouse serum. Data are reported as the mean of assay replicates. c r-PfCSP ELISA ( N = 20 per group for UPenn 3x, TriLink 2x) ( N = 19, TriLink 3x) ( N = 10, LNP1 alone), d fine specificity ELISA against the (NANP) 6 repeat peptide ( N = 20 per group for UPenn 3x, TriLink 2x) ( N = 19, TriLink 3x), e fine specificity ELISA are reported as the ratio of the (NANP) 6 titer to the α-TSR titer ( N = 20, UPenn) ( N = 17 per group for TriLink 3x, TriLink 2x), f the ratio of r-PfCSP IgG subclass titers for IgG1 and IgG2a ( N = 20, UPenn 3x) ( N = 18, TriLink 3x) ( N = 19, TriLink 2x) and g r-PfCSP avidity ELISA ( N = 20, UPenn 3x) ( N = 19 per group for TriLink 3x, TriLink 2x). Uninfected, infected, and unchallenged mice are represented by black, red, and gray symbols, respectively. Data in the bar graph are reported as the GM with 95% CI. All statistical analyses were performed using one-way ANOVA on ranks, Kruskal–Wallis post hoc Dunn’s multiple comparison test (** p < 0.01; **** p < 0.0001).

Article Snippet: To explore a single-dose regimen and an extended interval between doses for PfCSP mRNA (TriLink), mice were immunized either once with a 30 µg dose PfCSP mRNA-LNP1 (0–30 µg) or twice with 10 µg doses in a 3 week interval (0,3 - 10 µg) or 4 week interval (0,4 - 10 µg).

Techniques: Transgenic Assay, Injection, Functional Assay, Activity Assay, Inhibition, Enzyme-linked Immunosorbent Assay, Infection

Journal: Frontiers in Medicine

Article Title: SARS-CoV-2-Specific Antibody (Ab) Levels and the Kinetic of Ab Decline Determine Ab Persistence Over 1 Year

doi: 10.3389/fmed.2022.822316

Figure Lengend Snippet: (A,B) Decline kinetics for (A) NT_50 titers 1: x, % inhibition in sVNT, S1-specific IgG in BAU/ml and RBD-specific IgG in IU/ml post-infection and 3 months, 6 months and 1 year thereafter. Geometric mean titers & 95% CI of NT_50 titers, geometric means & 95% CI of S1-specific IgG, RBD-specific IgG, and % inhibition in sVNT; fast corresponds to ß 1 and slow to ß 2 in Eq. 1 (see text); and (B) S1-specific IgG in BAU/ml (geometric mean & 95% CI) in infected individuals and healthy controls vaccinated twice (4-week interval) with SARS-CoV-2 mRNA vaccine (post-infection/vaccination and after 6 months).

Article Snippet: Healthy control subjects enrolled in an ongoing SARS-CoV-2 vaccination study received 2 doses of an mRNA vaccine (BNT1622b2 [BioNTech/Pfizer] or mRNA-1273 [Moderna]) at a 4 weeks interval.

Techniques: Inhibition, Infection

Journal: JAMA Network Open

Article Title: Association of Self-reported High-Risk Allergy History With Allergy Symptoms After COVID-19 Vaccination

doi: 10.1001/jamanetworkopen.2021.31034

Figure Lengend Snippet: Baseline Characteristics Stratified by History of High-Risk Allergy Among Employees Who Received mRNA COVID-19 Vaccine

Article Snippet: We prospectively studied Mass General Brigham employees who received at least 1 dose of an mRNA COVID-19 vaccine and completed at least 1 postvaccination symptom survey assessment.

Techniques:

Journal: bioRxiv

Article Title: Machine Learning–Driven Antigen Selection Reveals Conserved T-Cell Targets for Broad Coronavirus Vaccination

doi: 10.64898/2026.04.02.716054

Figure Lengend Snippet: ( A ) Design of RNA constructs NEC-T4–T6. ( B ) Protein expression kinetics following transfection of Expi293F cells with mRNA constructs at 6, 24, and 48 h. Curves display construct-specific expression trends as log₂ intensity measured by DIA-NN. ( C ) Relative abundance of vaccine-derived proteins compared with the global proteome. Proteins were ranked by mean log₂ intensity across time points; vaccine-derived proteins are highlighted relative to endogenous proteins. ( D-E ). Immunogenic peptides included in the NEC-T4 and NEC-T5 constructs. β-CoV subgenera (top panel) and taxa (bottom panel) counts are shown. ( F-G ) Sarbecovirus-specific conservation. Bars show the number of peptides conserved in each combination of SARS-CoV (SARS-CoV-1 ∪ SARS-CoV-2), bat, and pangolin CoVs.

Article Snippet: Ex vivo validation of T-cell reactivity was performed using PBMCs isolated from healthy donors who had received at least two doses of an mRNA SARS-CoV-2 vaccine (Moderna/mRNA-1273 or Pfizer/BioNTech BNT162b2) and had experienced SARS-CoV-2 infection.

Techniques: Construct, Expressing, Transfection, Derivative Assay

Journal: Molecular Pharmaceutics

Article Title: Current Status and Future Perspectives on MRNA Drug Manufacturing

doi: 10.1021/acs.molpharmaceut.2c00010

Figure Lengend Snippet: Murine Preclinical Study Parameters for Pfizer/BioNTech and Moderna SARS-CoV-2 Vaccines a

Article Snippet: In murine immunogenicity trials, Pfizer/BioNTech considered an mRNA dose range of 0.2–1 μg, while Moderna explored a range of 0.0025–20 μg.

Techniques: Vaccines, Formulation

Journal: Vaccines

Article Title: Initial Mix-and-Match COVID-19 Vaccination Perceptions, Concerns, and Side Effects across Canadians

doi: 10.3390/vaccines10010093

Figure Lengend Snippet: Demographic characteristics of participants ( N = 1002).

Article Snippet: Thus, those who received the adenoviral vector vaccine first were more likely to switch to an mRNA dose later on when Pfizer-BioNTech and Moderna became more readily available, especially due to the safety concerns and risks of Oxford-AstraZeneca in younger adults (under 55) in Canada and other countries across the world [ , , ].

Techniques: Infection

Journal: Vaccines

Article Title: Initial Mix-and-Match COVID-19 Vaccination Perceptions, Concerns, and Side Effects across Canadians

doi: 10.3390/vaccines10010093

Figure Lengend Snippet: Total average amount of self-reported side effects after each vaccination by brand of vaccine ( N = 1002).

Article Snippet: Thus, those who received the adenoviral vector vaccine first were more likely to switch to an mRNA dose later on when Pfizer-BioNTech and Moderna became more readily available, especially due to the safety concerns and risks of Oxford-AstraZeneca in younger adults (under 55) in Canada and other countries across the world [ , , ].

Techniques: